*ST太安(002433) - 2015 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 25.28% to CNY 96,507,994.08 for the current period[5] - Operating revenue reached CNY 716,356,924.80, reflecting a growth of 100.68% year-on-year[5] - Basic earnings per share rose by 7.69% to CNY 0.14 for the current period[5] - The weighted average return on equity was 2.51%, a decrease of 0.40% compared to the previous period[5] - The company reported a total of CNY 2,300,299.17 in non-recurring gains and losses for the year-to-date[6] - Investment income increased by 1,940,334.23 CNY, a growth of 100.00%, due to returns from bank principal-protected financial products[14] - The net profit for 2014 was 18,630.69 million CNY, indicating a significant increase in profitability driven by growth in drug production and sales[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,766[8] - The largest shareholder, Taian Tang Group Co., Ltd., held 28.37% of the shares, amounting to 206,176,501 shares[8] - There were no significant changes in the shareholding structure among the top ten shareholders during the reporting period[9] Cash Flow and Investments - The net cash flow from operating activities showed a significant decline, amounting to -CNY 387,040,301.83, a decrease of 460.22%[5] - Cash and cash equivalents decreased by 232,091,873.26 CNY, a decline of 34.29%, mainly due to increased investment in engineering projects[12] - Cash flow from investment activities increased by 774,445,514.65 CNY, a growth of 104.94%, due to the receipt of matured investment funds[17] - Cash flow from financing activities decreased by 1,259,814,014.19 CNY, a decline of 91.40%, primarily due to last year's fundraising from a private placement[18] Operating Costs and Revenue - Operating costs rose by 618,588,396.24 CNY, an increase of 126.15%, in line with the growth in operating revenue[14] - Sales expenses increased by 134,578,712.57 CNY, a growth of 217.56%, due to higher advertising, marketing, and logistics costs[14] - Operating revenue increased by 807,720,700.79 CNY, a growth of 100.85%, primarily due to the business income from the subsidiary Guangdong Kang Aido Chain Pharmacy Co., Ltd.[12] Future Commitments and Dividends - The company has committed to distributing at least 30% of the average annual distributable profit in cash over the next three years, barring any major investment plans or significant cash expenditures[20] - The company will prioritize cash distribution of dividends, ensuring that at least 10% of the annual distributable profit is allocated in cash each year[20] - The company is currently fulfilling its commitment to avoid and eliminate competition within the same industry as per the agreement made on March 1, 2008[19] Other Financial Information - Total assets increased by 5.07% to CNY 4,721,172,884.35 compared to the end of the previous year[5] - There are no outstanding commitments or unfulfilled obligations reported for the current period[21] - The company does not hold any securities investments during the reporting period[23] - The company has not held any equity in other listed companies during the reporting period[24]